Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Accenture
Teva
Fuji
Medtronic
Queensland Health
Covington
Colorcon

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,580,830

« Back to Dashboard

Which drugs does patent 8,580,830 protect, and when does it expire?

Patent 8,580,830 protects ZUPLENZ and is included in one NDA.

This patent has fourteen patent family members in eleven countries.
Summary for Patent: 8,580,830
Title:Non-mucoadhesive film dosage forms
Abstract: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.
Inventor(s): Leichs; Christian (Alfdorf, DE), Breitenbach; Armin (Leverkusen, DE), Lehrke; Ingo (Cologne, DE), Galfetti; Paolo (Comasco, IT)
Assignee: Labtec GmbH (DE) APR Applied Pharma Research S.A. (CH)
Application Number:12/443,414
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound;

Drugs Protected by US Patent 8,580,830

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Midatech Pharma Us ZUPLENZ ondansetron FILM;ORAL 022524-001 Jul 2, 2010 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Midatech Pharma Us ZUPLENZ ondansetron FILM;ORAL 022524-002 Jul 2, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,580,830

PCT Information
PCT FiledOctober 02, 2007PCT Application Number:PCT/EP2007/008579
PCT Publication Date:April 10, 2008PCT Publication Number: WO2008/040534

Non-Orange Book US Patents Family Members for Patent 8,580,830

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,682,037 Non-mucoadhesive film dosage forms ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,580,830

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico 2009003372 ➤ Try a Free Trial
South Korea 101448050 ➤ Try a Free Trial
South Korea 20090080037 ➤ Try a Free Trial
European Patent Office 2444072 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
AstraZeneca
Citi
Fish and Richardson
Mallinckrodt
Boehringer Ingelheim
Chinese Patent Office
Argus Health
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.